Skip to Content

Potential as new standard treatment of HER2+ metastatic breast cancer

The results of the DESTINY-Breast03 study was presented at Presidential symposium, ESMO 2021 by Javier Cortés, MD, head of International Breast Cancer Center in Barcelona. DESTINY-Breast03 study are a multicenter, open-label, randomized phase 3 study comparing the efficacy and safety of trastuzumab deruxtecan vs trastuzumab emtansine for patients with HER2+ metastatic breast cancer. According to Javier Cortés This study will lead to a paradigm shift in the treatment of HER2+ metastatic breast cancer, because trastuzumab deruxtecan have the potential to be the new standard treatment for this group.

Javier Cortes Castan

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top